GENE ONLINE|News &
Opinion
Blog

2024-01-19| Manufacturing

AstraZeneca Invests $26.5 Million in New Production Line for Diabetes Drug in China

by Sinead Huang
Share To

UK pharmaceutical giant AstraZeneca is set to invest $26.5 million to establish a new production line at its Taizhou base in China. The move is part of the company’s expansion plans to manufacture a recently approved diabetes drug for the Chinese market. The investment and cooperation deal with the Taizhou Medical Hi-Tech Zone was formalized on January 13, highlighting AstraZeneca’s commitment to meeting the growing demand for diabetes treatment in China.

Related article: AstraZeneca’s Forxiga Gets EU Nod To Treat Symptomatic Chronic Heart Failure

141 Million Patients Fuel China’s Diabetes Drug Boom: AstraZeneca Joins the Fray

China, with a staggering 141 million diabetes patients in 2021, sees a rising demand for effective hypoglycemic drugs, particularly for the treatment of type-2 diabetes. The newly approved drug, Xigduo XR, dapagliflozin and metformin hydrochloride extended-release tablets, aligns with AstraZeneca’s efforts to contribute to combating diabetes in the country. The pharmaceutical company aims to cater to this significant market need by establishing a production line dedicated to this diabetes medication.

Taizhou Expansion Soars Towards $1.4 Billion Impact in China

AstraZeneca’s Taizhou production base, operational since 2014, initially focused on supplying diabetes products globally. With the introduction of the new production line, the facility is poised to have a substantial impact, anticipating an annual output value of $1.4 billion. The expansion aligns with AstraZeneca’s broader strategy to strengthen its presence in the Chinese pharmaceutical market and contribute to addressing the healthcare challenges posed by diabetes.

Having entered the Chinese market in 1993, AstraZeneca has consistently demonstrated its commitment to innovation and healthcare advancements. The company’s substantial investment of over $2 billion and the introduction of nearly 40 innovative drugs underscore its dedication to the Chinese market. In 2022, AstraZeneca’s sales in China reached $4.5 billion, constituting approximately 13 percent of its global sales. With the new investment, AstraZeneca aims to further solidify its position and contribute to healthcare solutions in China.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
2024-03-01
R&D
Semaglutide-Based Medications, Ozempic and Wegovy, Show Lower Suicidal Ideation Risk
2024-01-17
JPM 2024: AZ, Ginkgo and Moderna Provides Business Updates, Illustrating Optimistic Prospects
2024-01-11
LATEST
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
2024-03-01
An Interview with the Inventor of HPV Vaccine, Ian Frazer, Building a Firewall for Public Health
2024-02-29
Taiwan’s Drug Price Adjustments: Balancing Cost and Availability
2024-02-28
Neomorph Links Together With Novo Nordisk in a $1.46 Billion Molecular Glue Partnership Deal
2024-02-27
Breakthrough Study Shows Anti-IgE Antibody Safeguards Children with Multiple Food Allergies
2024-02-27
Cortisol: New Discoveries on its Impact Across Health, Culture, and Evolution
2024-02-26
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
EVENT
Scroll to Top